Comparison · NCT01042522-deaths
Arm I (Paclitaxel, Carboplatin) vs Arm II (Bleomycin Sulfate, Etoposide Phosphate, Cisplatin): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Paclitaxel, Carboplatin) vs Arm II (Bleomycin Sulfate, Etoposide Phosphate, Cisplatin): deaths from any cause. Trial comparisons, record NCT01042522-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01042522-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.161 | 0.0709 | 0.326 | wilson | |
| Risk in group 2 | 0.25 | 0.133 | 0.421 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0887 | -0.282 | 0.114 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.645 | 0.237 | 1.76 | log | |
| Odds ratio, group 1 over group 2 | 0.577 | 0.166 | 2.01 | log | |
| Number needed to treat, for one fewer death from any cause on Arm I (Paclitaxel, Carboplatin) than on Arm II (Bleomycin Sulfate, Etoposide Phosphate, Cisplatin) | 11.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Paclitaxel, Carboplatin) | Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Carboplatin: Given IV~Laboratory Biomarker Analysis: Correlative studies~Paclitaxel: Given IV | 5 | 31 | EG000 |
| Group 2 | Arm II (Bleomycin Sulfate, Etoposide Phosphate, Cisplatin) | Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Bleomycin Sulfate: Given IV~Cisplatin: Given IV~Etoposide Phosphate: Given IV~Laboratory Biomarker Analysis: Correlative studies | 8 | 32 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- The adverse events were assessed during the treatment period and up to 100 days after stopping study treatment (an average of 33 months).
Source ClinicalTrials.gov
Trial
- Title
- Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
- NCT number
- NCT01042522
- Phases
- PHASE2
- Conditions
Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified, Ovarian Steroid Cell Tumor
- Interventions
- Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Laboratory Biomarker Analysis, Paclitaxel
- Lead sponsor
- GOG Foundation
- Results first posted
- 2022-01-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01042522?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01042522-deaths